Related Experiment Videos
Metastatic follicular carcinoma associated with hyperthyroidism
Francisco Rosário1, Ana Rita Marques, Lúcia Roque
1Serviço de Endocrinologia, Instituto Português de Oncologia Francisco Gentil, CROL, SA, Lisboa, Portugal. francisrosario@netcabo.pt
Clinical Nuclear Medicine
|January 14, 2005
Summary
This case study details a rare follicular thyroid carcinoma with hyperthyroidism and bone metastases. Radioactive iodine (I-131) treatment offered only temporary relief for hyperthyroidism, with the exact cause remaining elusive.
Area of Science:
- Endocrinology
- Oncology
- Genetics
Background:
- Follicular thyroid carcinoma can present with metastatic disease and endocrine dysfunction.
- Hyperthyroidism in the context of thyroid cancer requires careful investigation of underlying mechanisms.
Observation:
- A 68-year-old male with metastatic follicular thyroid carcinoma exhibited T3 hyperthyroidism and intense radioactive iodine (I-131) uptake in the thyroid and bone metastases.
- Hyperthyroidism persisted post-thyroidectomy and was only transiently managed by I-131 therapy.
- Molecular analyses ruled out common mutations in the thyrotropin receptor and Gs alpha subunit, and thyroid-stimulating receptor antibodies were unlikely causes.
Findings:
- Comparative genomic hybridization revealed multiple chromosomal imbalances in the tumor.
- I-131 treatment provided only a 9-month euthyroid state, with no impact on tumor progression.
- The precise etiology of the persistent hyperthyroidism remained undetermined, with type 2 deiodinase overexpression being unlikely due to genetic findings.
Implications:
- This case highlights the complexity of managing hyperthyroidism associated with metastatic follicular thyroid carcinoma.
- Further research is needed to elucidate the mechanisms driving hormone production in such rare thyroid cancer presentations.
- Understanding the genetic underpinnings of thyroid cancer-associated hyperthyroidism is crucial for developing effective therapeutic strategies.